This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
RE-DUAL PCI was a randomized, parallel-design phase 4 treatment study evaluating two dabigatran-based dual-therapy strategies in ACS patients with an indication for NOAC undergoing PCI.
Enrollment
Arms
Primary endpoint timeframe
Study phase
| Feature | RE-DUAL PCI |
|---|---|
| NCT ID | NCT04688723 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | Zuyderland Medisch Centrum |
| Sponsor type | Other |
2. Clinical Question
Population
ACS patients with indication for NOAC undergoing PCI.
Intervention
Dabigatran plus ticagrelor.
Comparator
Dabigatran plus clopidogrel.
Primary question
The registry evaluates bleeding outcomes between the two dual-therapy strategies.
3. Trial Design
1000 patients
12 months
Arm A
Dabigatran + Ticagrelor (drug).
Arm B
Dabigatran + clopidogrel (drug).
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Bleeding | Bleeding defined as BARC bleeding score ≥2 | 12 months |
5. Planned Analysis
The ClinicalTrials.gov record identifies bleeding defined as BARC bleeding score ≥2 at 12 months as the primary endpoint. Results have not been posted on ClinicalTrials.gov.
For a randomized comparison of bleeding outcomes, statistical analysis would typically compare the proportion of patients experiencing the endpoint between treatment groups using methods appropriate for binary clinical outcomes. The analysis framework would depend on the prespecified statistical analysis plan, including the intended estimand, analysis population, and handling of missing outcome information.
6. Statistical Methodology
The trial design uses random allocation to compare two treatment strategies. Randomization is intended to balance known and unknown prognostic factors between groups, allowing differences in outcomes to be interpreted as treatment-group comparisons.
Binary endpoint analysis
A bleeding endpoint defined by whether a patient experiences BARC bleeding score ≥2 is a categorical outcome. A common statistical framework compares event proportions:
Risk difference = p₁ − p₂
Risk ratio = p₁ / p₂
The clinical interpretation depends on the prespecified effect measure and uncertainty around the estimate.
7. Statistical Methods Explained
Why does randomization matter?
Randomization creates treatment groups through chance assignment rather than clinical selection. This reduces confounding and supports causal comparison of the randomized strategies.
What does a bleeding endpoint measure?
A bleeding endpoint based on BARC bleeding score ≥2 classifies whether clinically relevant bleeding occurred according to the registry definition. It is different from measuring treatment exposure or medication adherence.
Why is the time frame important?
A 12-month endpoint specifies the observation period in which bleeding outcomes are evaluated. Changing the follow-up window can change the interpretation of event rates.
Why are confidence intervals important?
Confidence intervals describe uncertainty around an estimated treatment comparison. They provide information about statistical precision beyond a single point estimate.
Why does a p-value not measure clinical importance?
A p-value addresses compatibility of observed data with a statistical hypothesis. It does not describe the size of a treatment difference or its clinical relevance.
8. Limitations
- Results availability: The registry does not report posted statistical analyses or endpoint results.
- Analysis details: The registry information does not describe the statistical analysis plan, missing-data approach, or multiplicity strategy.
- Generalizability: Interpretation depends on the characteristics of patients represented in ACS populations with NOAC indication undergoing PCI.
- Endpoint interpretation: Bleeding outcomes represent one component of treatment comparison and do not alone summarize all clinical effects.
9. Why This Trial Matters Statistically
| Concept | How it appears in RE-DUAL PCI |
|---|---|
| Randomization | Parallel randomized treatment comparison. |
| Clinical endpoint definition | Bleeding defined as BARC bleeding score ≥2. |
| Binary outcomes | Bleeding event occurrence over a defined timeframe. |
| Comparative effectiveness | Two dabigatran-based dual-therapy strategies. |
| Time horizon | 12-month endpoint assessment. |
10. Sources
- ClinicalTrials.gov record: RE-DUAL PCI (NCT04688723)